Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
Portfolio Pulse from Lara Goldstein
In the Benzinga Psychedelics Podcast, Zappy Zapolin discusses the future of psychedelics, highlighting the industry's potential mainstream breakthrough in 2024 with federal legalization of MDMA for PTSD, psychedelics legalization campaigns, and COMPASS Pathways' commercialization. Zapolin, involved with companies like KetaMD (acquired by Braxia Scientific, OTC:BRAXF) and Psycheceutical Bioscience (OTC:BWVI), also launches guided psychedelic retreats, emphasizing the importance of medical supervision in therapy.
February 29, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Braxia Scientific, having acquired KetaMD, is directly involved in the psychedelics space, which is expected to gain mainstream attention and investment in 2024.
Braxia's acquisition of KetaMD positions it well in the psychedelics market, which is anticipated to grow significantly with the potential federal legalization of MDMA for PTSD and increased investor interest in 2024.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Psycheceutical Bioscience, with Zappy Zapolin as chief visionary officer, is part of the evolving psychedelics industry, poised for growth with the sector's expected mainstream acceptance in 2024.
With Zapolin's involvement and the industry's anticipated mainstream breakthrough in 2024, Psycheceutical Bioscience is likely to benefit from the increased attention and investment in the psychedelics sector.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
COMPASS Pathways is highlighted as a key player in the psychedelics industry, with its commercialization efforts marking a watershed moment for institutional investment in 2024.
COMPASS Pathways' commercialization efforts are seen as a critical milestone for the psychedelics industry, potentially attracting significant institutional investment and contributing to the sector's mainstream acceptance in 2024.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 90